Terms: = Endocrine gland cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
94 results:
1. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
2. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract] [Full Text] [Related]
3. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
4. Optimized spirooxindole-pyrazole hybrids targeting the p53-mdm2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.
Islam MS; Al-Majid AM; Sholkamy EN; Barakat A; Viale M; Menichini P; Speciale A; Loiacono F; Azam M; Verma VP; Yousuf S; Teleb M
Sci Rep; 2023 May; 13(1):7441. PubMed ID: 37156796
[TBL] [Abstract] [Full Text] [Related]
5. treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract] [Full Text] [Related]
6. Expression and Clinical Significance of mdm2 in Non-Functioning PitNETs.
Yao X; Liu Q; Zhao S; Cheng R; Liu C; Zhang G
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837574
[No Abstract] [Full Text] [Related]
7. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
8. Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer.
Malhotra L; Sharma S; Hariprasad G; Dhingra R; Mishra V; Sharma RS; Kaur P; Ethayathulla AS
Biochim Biophys Acta Mol Cell Res; 2022 Dec; 1869(12):119343. PubMed ID: 36007676
[TBL] [Abstract] [Full Text] [Related]
9. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract] [Full Text] [Related]
10. Enhancement of mdm2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
11. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
Timmerman DM; Eleveld TF; Sriram S; Dorssers LCJ; Gillis AJM; Schmidtova S; Kalavska K; van de Werken HJG; Oing C; Honecker F; Mego M; Looijenga LHJ
J Clin Oncol; 2022 Sep; 40(26):3077-3087. PubMed ID: 35442716
[TBL] [Abstract] [Full Text] [Related]
12. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
[TBL] [Abstract] [Full Text] [Related]
13. p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid cancer and Autoimmunity.
Arena A; Stigliano A; Belcastro E; Giorda E; Rosado MM; Grossi A; Assenza MR; Moretti F; Fierabracci A
Front Immunol; 2021; 12():728381. PubMed ID: 34539667
[TBL] [Abstract] [Full Text] [Related]
14. Clinical utility of the imunohistochemical co-expression of p53 and mdm2 in thyroid follicular lesions.
Martins MB; de Assis Batista F; Marcello MA; Bufalo NE; Peres KC; Morari EC; Soares FA; Vassallo J; Ward LS
Ann Diagn Pathol; 2021 Aug; 53():151766. PubMed ID: 34111705
[TBL] [Abstract] [Full Text] [Related]
15. Genetic variants and risk of thyroid cancer among Iranian patients.
Jamshidi M; Farnoosh G; Mohammadi Pour S; Rafiee F; Saeedi Boroujeni A; Mahmoudian-Sani MR
Horm Mol Biol Clin Investig; 2021 Feb; 42(2):223-234. PubMed ID: 33544997
[TBL] [Abstract] [Full Text] [Related]
16. Sodium cantharidinate, a novel anti-pancreatic cancer agent that activates functional p53.
Liu X; Zhang L; Thu PM; Min W; Yang P; Li J; Li P; Xu X
Sci China Life Sci; 2021 Aug; 64(8):1295-1310. PubMed ID: 33165811
[TBL] [Abstract] [Full Text] [Related]
17. Anti-cancer Tumor Cell Necrosis of Epithelial Ovarian cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
[TBL] [Abstract] [Full Text] [Related]
18. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
Cui Y; Zhou J; Rong F
Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
[TBL] [Abstract] [Full Text] [Related]
19. Standardized Saponin Extract from Baiye No.1 Tea (
Tu Y; Chen L; Ren N; Li B; Wu Y; Rankin GO; Rojanasakul Y; Wang Y; Chen YC
Molecules; 2020 Jul; 25(15):. PubMed ID: 32752095
[TBL] [Abstract] [Full Text] [Related]
20. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y; Nagasaka K; Oda K; Makii C; Takeuchi M; Oki S; Honjo H; Kojima M; Miyagawa Y; Taguchi A; Tanikawa M; Sone K; Hiraike H; Matsumoto Y; Wada-Hiraike O; Ayabe T; Osuga Y; Fujii T
Cancer Sci; 2020 Oct; 111(10):3824-3834. PubMed ID: 32713096
[TBL] [Abstract] [Full Text] [Related]
[Next]
